Gene Network Sciences Announces Cancer Treatment Collaboration With Weill Cornell Medical College
Posted on: Wednesday, 20 June 2007, 12:00 CDT
CAMBRIDGE, Mass., June 20 /PRNewswire/ -- Gene Network Sciences (GNS) today announced that it has entered into a cancer treatment collaboration with the Weill Cornell Medical College (WCMC). Financial terms of the agreement were not disclosed.
Under the agreement, the parties will use GNS's proprietary REFS(TM) (reverse engineering and forward simulation) software platform to characterize the synergies between two commonly used classes of cancer drugs, farnesyl transferase inhibitors (FTIs) and taxanes.
"Phase I and II clinical trials have shown that the combination of FTIs and taxanes have clinical activity in taxane-refractory cancer patients," said Dr. Paraskevi Giannakakou, Weill Cornell's principal investigator for the collaboration and a leading authority on the mechanism of action of taxane-like drugs. "Discovering the molecular mechanism of action of this combination will pave the way towards identifying subsets of patients likely to benefit from this drug combination and will assist the rational development of therapeutic strategies able to overcome clinical drug resistance."
WCMC will use novel techniques to generate molecular-level data from the use of these drugs in model cancer systems. GNS will then build "in silico" models containing FTIs and taxanes together, allowing the parties to elucidate these drugs' synergistic mechanisms of efficacy and toxicity, biomarkers, and related biological insights.
"Our REFS(TM) technology provides the ability to simulate multiple drugs' activity in a disease system in a single model," said Colin Hill, CEO of GNS. "We aim through our collaborative research approach to develop better treatment options for cancer patients."
About Gene Network Sciences
Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com/) is a privately held biosimulation company with offices in Cambridge, Massachusetts, and Ithaca, New York. The company's REFS(TM) (reverse engineering and forward simulation) technology rapidly turns complex and heterogeneous data sets into cell and organ-level computer models able to simulate the clinical performance of drugs and drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology increases pharmaceutical companies' confidence in advancing drug candidates and ultimately improves clinical trial success rates.
Gene Network Sciences
CONTACT: Thomas A. Neyarapally, Vice President, Corporate Strategy &Intellectual Property of Gene Network Sciences, +1-617-494-0492, ext. 238,fax, +1-617-494-0114, tneyarapally@gnsbiotech.com
Web site: http://gnsbiotech.com/
Source: PRNewswire
Related Articles
- NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
- Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
- Enzon's PEG-SN38 Featured in Clinical Cancer Research
- Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
- 'The Drug Target Atlas of Apoptopic Drugs in Oncology' Reports on 90 Unique Drug Target Combinations
- Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
- Chemo Drug Helps Cancer-Killing Virus
- Application of Sentinel Principle in Bladder Cancer Published in Clinical Cancer Research
- Experimental Drug Stuns Cancer Doctors
 |
 |
User Comments (0)
RSS Feeds